ArticleHealth science reports2025
Prospective, Randomized, Double-Blind Assessment of Supramolecular Bakuchiol and Terminalia Chebula Extract for Facial Photoaging in Chinese Sensitive Skin Population.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Asian skin is more sensitive than Caucasian. When it comes to anti-aging treatments, some classic actives like Retinoids, are not friendly to Asian skin due to irritation issues. Therefore, it becomes more important to research new active ingredients to address the aging concern of sensitive skin. To clinically assess the anti-aging, skin soothing, barrier function improvement efficacy of one novel formulation containing supramolecular Bakuchiol and Terminalia chebula extract in Chinese sensitive skin population. Methods: A total of 34 sensitive skin subjects were enrolled in this clinical efficacy study. A routine consisting of twice daily topical applications of the test serum was followed for 28 days, evaluations were performed at baseline (D0) and after 8 h (T8h), 14 days (D14) and 28 days (D28) of using the regime. Objective skin assessment principles are skin sensitivity, barrier and aging. Sensitivity was evaluated by lactic acid sting test (LAST). Skin barrier evaluation, including transepidermal water loss (TEWL), a* value, and redness percentage. Aging evaluation, including wrinkle area, skin wrinkle (SEw), elasticity (R2), firmness (F4). As well as dermatologist evaluation of skin sensitivity and aging parameters and safety assessment. Results: TEWL, a* value, redness percentage and mean score of LAST significantly reduced by 24.90%, 10.76%, 31.81%, 28.09%, respectively, and Dermatologist assessment significant decrease in facial redness, after 28 days of skin care treatment with the test serum. Wrinkle area, SEw, F4 significantly reduced by 16.06%, 16.71%, 25.60%, respectively, and Dermatologist assessment significant decrease in facial wrinkles, while R2 significantly increased by 23.04% after 28 days. No adverse events were reported. Conclusions: The serum containing supramolecular Bakuchiol and Terminalia chebula extract achieved skin rejuvenation in sensitive skin by improving sensitive and aging skin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.